Boehringer and Lilly’s Jardiance Hits Mark in Decreasing Risk of Death in Heart Failure

Jul 31, 2020 | Cardiovascular, News, Positive Results

Boehringer and Lilly’s Jardiance Hits Mark in Decreasing Risk of Death in Heart Failure

Boehringer and Eli Lilly announced positive results from the EMPEROR-Reduced Phase III trial in adults with heart failure with reduced ejection fraction, with and without diabetes. The trial met the primary endpoint of superiority versus placebo in decreasing the risk of a composite of cardiovascular death or hospitalization from heart failure when added to standard of care. Full results from the EMPEROR-Reduced trial will be presented in a hot line session at the European Society of Cardiology (ESC) Congress 2020 on August 29, and regulatory submissions are planned in 2020. 

A second trial, EMPEROR-Preserved, is exploring the effect of Jardiance on cardiovascular death or hospitalization in adults with heart failure with preserved ejection fraction – an area with no approved treatment options. EMPEROR-Preserved results are expected in 2021.

The EMPEROR (EMPagliflozin outcomE tRial in patients with chrOnic heaRt failure) heart failure studies are both randomized, double-blind trials to investigate once-daily Jardiance compared with placebo in adults with heart failure with preserved or reduced ejection fraction, both with and without diabetes, who are receiving current standard of care.

About Jardiance 

Jardiance is a sodium-glucose co-transporter 2 (SGLT2) inhibitor.

Jardiance is approved for use along with diet and exercise to lower blood sugar in adults with type 2 diabetes. Jardiance is also used to reduce the risk of cardiovascular death in adults with type 2 diabetes who have known cardiovascular disease.

About Heart Failure

Heart failure is a progressive, debilitating and potentially fatal condition that occurs when the heart cannot supply adequate circulation to meet the body’s demands for oxygenated blood or to do so requires increased blood volume leading to fluid accumulation (congestion) in the lungs and peripheral tissues. It is a widespread condition affecting 60 million people worldwide and expected to increase as the population ages. Heart failure is highly prevalent in people with diabetes; however, approximately half of all people with heart failure do not have diabetes.

Source: Eli Lilly

0 Comments

Pin It on Pinterest